Orchestra BioMed Inc. (OBIO)
3.17
-0.35 (-9.94%)
At close: Apr 03, 2025, 3:59 PM
3.05
-3.79%
After-hours: Apr 03, 2025, 04:27 PM EDT
-9.94% (1D)
| Bid | 2.37 |
| Market Cap | 121.45M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.6 |
| PE Ratio (ttm) | -1.98 |
| Forward PE | -2.79 |
| Analyst | Buy |
| Ask | 3.87 |
| Volume | 44,369 |
| Avg. Volume (20D) | 62,570 |
| Open | 3.53 |
| Previous Close | 3.52 |
| Day's Range | 3.14 - 3.41 |
| 52-Week Range | 3.07 - 8.87 |
| Beta | 0.59 |
About OBIO
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collabora...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 4, 2020
Employees 70
Stock Exchange NASDAQ
Ticker Symbol OBIO
Website https://orchestrabiomed.com
Analyst Forecast
According to 5 analyst ratings, the average rating for OBIO stock is "Buy." The 12-month stock price forecast is $14.5, which is an increase of 357.41% from the latest price.
Stock ForecastsEarnings Surprise
Orchestra BioMed has released their quartely earnings
on Mar 31, 2025:
Next Earnings Release
Orchestra BioMed Inc. is scheduled to release its earnings on May 12, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 days ago
-24.3%
Orchestra BioMed shares are trading lower after th...
Unlock content with
Pro Subscription
3 months ago
+34.5%
Orchestra BioMed shares are trading higher Barclays initiated coverage on the stock with an Overweight rating and announced a price target of $16.
